抗精子蛋白17单克隆抗体对人卵巢癌细胞SKOV-3的抑制作用
Inhibitory Effects of anti-Sp17 Monoclonal Antibody Against Human Ovarian Cancer Cell Line SKOV-3
-
摘要: 目的 观察抗精子蛋白17单克隆抗体(anti-Sperm protein 17 monoclonal antibody,anti-Sp17 mAb)对卵巢癌细胞系SKOV-3的体外抗肿瘤活性和机制。方法采用MTT法观察抗anti-Sp17 mAb对肿瘤细胞SKOV-3的细胞毒作用；以外周血单个核细胞PBMCs为效应细胞,SKOV-3为靶细胞,在效靶比分别为80∶1、40∶1和20∶1的条件下,观察anti-Sp17 mAb的抗体依赖性细胞介导的细胞毒作用；以SKOV-3为靶细胞,加入浓度为2.5%、5%、10%和20%的健康人新鲜血清作为补体,观察单抗的补体依赖性细胞毒性。结果anti-Sp17 mAb对SKOV-3无明显细胞毒作用；与对照组相比,单抗对SKOV-3的ADCC作用呈剂量依赖关系,在效靶比为80∶1,孵育24 h后,细胞生长抑制率约为22%；补体的加入也可显著提高单抗对SKOV-3细胞生长的抑制率,在血清浓度为5%,单抗浓度为10 μg/ml时抑制率达到了40%。结论anti-Sp17 mAb对表达Sp17蛋白的卵巢癌细胞株SKOV-3具有明显的ADCC和CDC效应。Abstract: Objective To investigate the inhibitory effect and mechanism of anti-Sp17 monoclonal antibody(mAb) on the growth of human ovarian cancer cells SKOV-3 in vitro. Methods Viability was assessed with the 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) assay after treatment with anti-Sp17 mAb.The ADCC and CDC activities of anti-Sp17 mAb were monitored using SKOV-3 cells as targets,healthy human peripheral blood monocytes and healthy human serum as effectors. Results Our preliminary results indicated that direct cytotoxicity of anti-Sp17 mAb against ovarian cancer cells was very low.However,the cytotoxic action of anti-Sp17 mAb mediated by PBMC,as ADCC,or mediated by human serum,as CDC,was noted in investigation of SKOV-3 cells. Conclusion anti-Sp17 mAb could provide a useful tool against ovarian cancer,and may provide insight into the development of low side-effect targeting therapy for this malignant disease.
下载:
